Now showing items 1-1 of 1

    • Phase I clinical trial repurposing all-trans retinoic acid as a stromal targeting agent for pancreatic cancer. 

      Kocher, HM; Basu, B; Froeling, FEM; Sarker, D; Slater, S; Carlin, D; deSouza, NM; De Paepe, KN; Goulart, MR; Hughes, C; Imrali, A; Roberts, R; Pawula, M; Houghton, R; Lawrence, C; Yogeswaran, Y; Mousa, K; Coetzee, C; Sasieni, P; Prendergast, A; Propper, DJ (2020-09-24)
      Pre-clinical models have shown that targeting pancreatic stellate cells with all-trans-retinoic-acid (ATRA) reprograms pancreatic stroma to suppress pancreatic ductal adenocarcinoma (PDAC) growth. Here, in a phase Ib, dose ...